Stepan Co Dossier - Source-backed chat

Stepan Co

SCLNYSE

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)0.97

Intrinsic Value $76.50median of 3 methodsbased on filings through 30 Jun 2026

Market Price $61.53Price as of 1 Oct 2026

UndervaluedIntrinsic value is 24% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.4B

Enterprise Value $1.9B

Shares Outstanding 22.9M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

Last ex-dividend1 Sep 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Stepan Company (NYSE: SCL) is undergoing a significant operational reset through 'Project Catalyst,' a comprehensive efficiency program targeting $100 million in pre-tax savings over the next two years. While Q1 2026 results were heavily impacted by a $65.4 million pre-tax restructuring charge, leading to a reported net loss of $41.4 million, the underlying business shows resilience. The company's strategic focus on ramping up its Pasadena, Texas facility to 80% utilization in 2026 and expanding its higher-margin functional surfactants (Tier 2 and Tier 3 specialty products) provides a clear path to EBITDA growth and positive free cash flow in the second half of 2026. Backed by a 58-year track record of consecutive annual dividend increases, Stepan offers a compelling risk-reward profile for patient, value-oriented investors as destocking headwinds in core chemical segments begin to ease.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$85.00

Mean target$85.00

High · most bullish analyst$85.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

In the bear case, persistent inflationary pressures and prolonged weakness in commodity consumer product end markets delay surfactant margin recovery. Execution risks associated with Project Catalyst lead to higher-than-expected cash decommissioning costs, while construction market weakness continues to depress polymer volumes. Elevated interest expenses and a higher leverage profile limit free cash flow, keeping the stock range-bound near its recent lows.

Base CaseCentral scenario

Under the base case, Stepan successfully executes Project Catalyst, capturing approximately 60% of the targeted $100 million pre-tax savings in 2026. The Pasadena, Texas facility ramps up to its 80% utilization target, driving supply chain efficiencies and supporting volume growth in specialty alkoxylates. Commodity surfactant demand stabilizes, and the company continues to pass through raw material cost fluctuations. This leads to a strong recovery in adjusted EBITDA and positive free cash flow generation in the second half of 2026, driving the stock toward its historical valuation multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Project Catalyst is on track to deliver $100 million in pre-tax savings over two years, with 60% expected to be realized in 2026.
The state-of-the-art Pasadena, Texas facility is ramping up, expected to reach 80% utilization in 2026 and drive long-term specialty alkoxylate growth.
An exceptional dividend track record with 58 consecutive years of annual dividend increases, demonstrating strong commitment to shareholder returns.
Pending $30 million sale of nonproductive Millsdale land in fall 2026 will further strengthen the balance sheet and reduce net debt.

Key Investment Risks

Execution risks and front-loaded cash costs associated with closing the Fieldsboro, NJ site and decommissioning other assets.
Continued demand softness and margin compression in commodity consumer surfactant end markets.
Higher interest expenses and elevated leverage, with total debt standing at $651.7 million as of Q1 2026.
Volatility in raw material and energy costs that may not be fully or immediately passed through to customers.

Thesis Invalidation Triggers

Failure to achieve the projected 60% of Project Catalyst savings in fiscal year 2026.
A significant delay in the Pasadena facility ramp-up, keeping utilization well below the 80% target.
Cancellation or material down-pricing of the pending $30 million Millsdale land sale.
A dividend cut or freeze, which would break the company's 58-year dividend growth streak and damage investor confidence.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.